copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Cambrian Bio The assets will be developed by new Cambrian subsidiary Tornado Therapeutics led by industry and Novartis veteran Joan Mannick, M D , as CEO The most advanced asset is now moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing
Cambrian bags mTOR inhibitors licensing agreement The rapamycin assets will be developed by new Cambrian subsidiary Tornado Therapeutics led by industry and Novartis veteran Joan Mannick, MD, as CEO The most advanced asset is now moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing
Cambrian launches new subsidiary to develop mTOR inhibitors Cambrian has added to its age-related disease portfolio via a deal with Novartis for a series of mTOR inhibitors that will be developed by newly launched subsidiary Tornado Therapeutics
Novartis Pipeline Discover the Novartis pipeline of over 100 projects in clinical development, many for medicines that could advance treatment standards for patients
Novartis - Wikipedia Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024 [4][5] Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate
Novartis Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information Discover how Novartis turns breakthrough science into transformative, high-value treatments